NYSE:CRL - Charles River Laboratories International Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $214.67
  • Forecasted Upside: -23.38 %
  • Number of Analysts: 18
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 13 Buy Ratings
  • 1 Strong Buy Ratings
$280.18
▼ -1.06 (-0.38%)
1 month | 3 months | 12 months
Get New Charles River Laboratories International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$214.67
▼ -23.38% Downside Potential
This price target is based on 18 analysts offering 12 month price targets for Charles River Laboratories International in the last 3 months. The average price target is $214.67, with a high forecast of $265.00 and a low forecast of $145.00. The average price target represents a -23.38% upside from the last price of $280.18.
Buy
The current consensus among 18 polled investment analysts is to buy stock in Charles River Laboratories International. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/1/2019
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/28/2020
  • 1 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/27/2020
  • 1 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/26/2020
  • 1 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/24/2020
  • 1 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/23/2020
  • 1 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/22/2021

Latest Recommendations

  • 1 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/22/2020ArgusBoost Price TargetBuy$235.00 ➝ $265.00Low
i
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ NeutralLow
i
12/16/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngradeBuy ➝ Neutral$270.00 ➝ $250.00N/A
i
11/24/2020KeyCorpBoost Price TargetOverweight$233.00 ➝ $256.00High
i
11/3/2020TruistBoost Price Target$237.00 ➝ $256.00Low
i
10/30/2020Morgan StanleyBoost Price TargetOverweight$245.00 ➝ $260.00Medium
i
10/30/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$235.00 ➝ $250.00Medium
i
9/14/2020ArgusBoost Price TargetBuy$190.00 ➝ $235.00Low
i
9/10/2020Jefferies Financial GroupUpgradeHold ➝ Buy$213.00 ➝ $254.00High
i
Rating by David Windley at Jefferies Financial Group Inc.
8/18/2020KeyCorpBoost Price TargetOverweight$186.00 ➝ $233.00Low
i
8/6/2020Morgan StanleyBoost Price TargetOverweight$175.00 ➝ $245.00Low
i
8/6/2020CitigroupBoost Price TargetBuy$190.00 ➝ $255.00Low
i
7/21/2020UBS GroupBoost Price TargetBuy$200.00 ➝ $236.00Low
i
7/1/2020Bank of AmericaUpgradeNeutral ➝ Buy$192.00Low
i
5/26/2020ArgusBoost Price TargetAverage ➝ Buy$150.00 ➝ $190.00Medium
i
5/13/2020UBS GroupUpgradeNeutral ➝ Buy$177.00 ➝ $200.00Low
i
5/12/2020Deutsche Bank AktiengesellschaftLower Price TargetBuy$190.00 ➝ $174.00Medium
i
5/8/2020JPMorgan Chase & Co.Boost Price TargetOverweight$160.00 ➝ $180.00Low
i
5/8/2020Robert W. BairdBoost Price TargetOutperform$156.00 ➝ $175.00Low
i
Rating by Eric Coldwell at Robert W. Baird
5/8/2020Credit Suisse GroupLower Price TargetNeutral$162.00 ➝ $159.00Low
i
5/8/2020Morgan StanleyBoost Price TargetOverweight$152.00 ➝ $175.00Medium
i
5/8/2020CitigroupBoost Price TargetBuy$165.00 ➝ $190.00Medium
i
5/8/2020SunTrust BanksBoost Price TargetBuy$130.00 ➝ $194.00Medium
i
4/21/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$139.00High
i
4/9/2020CitigroupLower Price TargetBuy$200.00 ➝ $165.00Medium
i
4/6/2020SunTrust BanksBoost Price TargetBuy$124.00 ➝ $130.00High
i
3/30/2020Wells Fargo & CompanyLower Price TargetOverweight$200.00 ➝ $145.00High
i
3/27/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$152.00High
i
3/26/2020BarclaysLower Price TargetEqual Weight$170.00 ➝ $154.00High
i
3/23/2020Jefferies Financial GroupLower Price TargetBuy$200.00 ➝ $139.00Medium
i
3/17/2020SunTrust BanksLower Price TargetBuy$188.00 ➝ $124.00High
i
3/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy$190.00High
i
2/18/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$169.00 ➝ $203.00Low
i
2/12/2020Morgan StanleyBoost Price TargetEqual Weight$156.00 ➝ $176.00Medium
i
2/12/2020Robert W. BairdReiterated RatingOutperform$165.00 ➝ $185.00Medium
i
2/12/2020BarclaysReiterated RatingHold$170.00Low
i
2/12/2020CitigroupBoost Price TargetBuy$185.00 ➝ $200.00Low
i
2/11/2020CfraBoost Price TargetStrong-Buy$165.00 ➝ $180.00Medium
i
1/10/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$143.00 ➝ $179.00Low
i
1/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$180.00Low
i
1/6/2020CitigroupInitiated CoverageBuy$185.00Low
i
12/17/2019Robert W. BairdBoost Price TargetOutperform$160.00 ➝ $165.00Medium
i
12/9/2019KeyCorpBoost Price TargetOverweight ➝ Overweight$151.00 ➝ $162.00Medium
i
11/19/2019ArgusReiterated RatingBuy$170.00Low
i
10/18/2019Bank of AmericaDowngradeBuy ➝ Neutral$150.00High
i
9/16/2019SunTrust BanksBoost Price TargetBuy ➝ Buy$156.00 ➝ $162.00Medium
i
9/13/2019Credit Suisse GroupSet Price TargetHold$138.00Medium
i
Rating by Erin Wright at Credit Suisse Group AG
6/10/2019SVB LeerinkInitiated CoverageOutperform$155.00Low
i
Rating by D. Larsen at SVB Leerink LLC
4/30/2019Evercore ISIReiterated RatingOutperform ➝ Outperform$160.00Low
i
4/2/2019Wolfe ResearchInitiated CoverageMarket PerformMedium
i
3/18/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$135.00 ➝ $145.00Medium
i
3/11/2019KeyCorpBoost Price TargetOverweight ➝ Overweight$140.00 ➝ $151.00Low
i
2/14/2019BarclaysReiterated RatingHold$135.00Low
i
2/14/2019SunTrust BanksBoost Price TargetPositive ➝ Buy$151.00Low
i
2/14/2019Jefferies Financial GroupReiterated RatingBuy$162.00Low
i
12/14/2018Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ BuyLow
i
12/4/2018Raymond JamesReiterated RatingBuy$150.00Low
i
Rating by Michael J. Baker at Raymond James
12/3/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$112.00 ➝ $136.00Low
i
Rating by Ricky Goldwasser at Morgan Stanley
11/8/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$144.00 ➝ $148.00Medium
i
11/8/2018Raymond JamesBoost Price TargetOutperform ➝ Buy$140.00 ➝ $150.00Medium
i
Rating by Michael J. Baker at Raymond James
11/7/2018Royal Bank of CanadaSet Price TargetOutperform ➝ Buy$131.00 ➝ $147.00N/A
i
Rating by George Hill at Royal Bank of Canada
10/9/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$140.00Low
i
9/25/2018Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral$121.00 ➝ $128.00High
i
9/17/2018Robert W. BairdBoost Price TargetOutperform$133.00 ➝ $141.00Low
i
9/11/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Hold$102.00 ➝ $112.00Low
i
Rating by Ricky Goldwasser at Morgan Stanley
8/27/2018ArgusBoost Price TargetBuy ➝ Buy$125.00 ➝ $140.00Low
i
8/23/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$140.00Medium
i
8/21/2018Credit Suisse GroupLower Price TargetNeutral ➝ Neutral$129.00 ➝ $121.00Low
i
8/9/2018BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$110.00 ➝ $120.00Medium
i
8/9/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$140.00 ➝ $145.00High
i
8/9/2018SunTrust BanksBoost Price TargetBuy$135.00Medium
i
7/20/2018Jefferies Financial GroupReiterated RatingBuy$140.00Low
i
7/17/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$131.00High
i
Rating by George Hill at Royal Bank of Canada
7/16/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$120.00 ➝ $125.00Low
i
6/15/2018KeyCorpUpgradeSector Weight ➝ Overweight$115.85 ➝ $130.00High
i
4/20/2018Mitsubishi UFJ Financial GroupInitiated CoverageNeutral$115.00Low
i
Rating by J. Twizell at Mitsubishi UFJ Financial Group
3/14/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$94.00 ➝ $102.00Low
i
2/16/2018BarclaysReiterated RatingHold$110.00Low
i
2/15/2018Credit Suisse GroupReiterated RatingHold$108.00Low
i
2/14/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$110.00 ➝ $120.00Medium
i
2/14/2018SunTrust BanksUpgradeHold ➝ Buy$107.66 ➝ $125.00Medium
i
2/13/2018Royal Bank of CanadaSet Price TargetHold$116.00High
i
Rating by George Hill at Royal Bank of Canada
2/13/2018Robert W. BairdSet Price TargetBuy$123.00High
i
Rating by Eric Coldwell at Robert W. Baird
1/22/2018SunTrust BanksDowngradeBuy ➝ Hold$107.89 ➝ $111.00Medium
i
1/18/2018Evercore ISIInitiated CoverageIn ➝ In-Line$117.00Low
i
12/13/2017ArgusInitiated CoverageBuy ➝ Buy$120.00Medium
i
11/17/2017SunTrust BanksReiterated RatingBuy$113.00N/A
i
11/13/2017Robert W. BairdSet Price TargetBuy$117.00N/A
i
11/10/2017Bank of AmericaLower Price TargetBuy$117.00 ➝ $115.00N/A
i
10/16/2017Credit Suisse GroupReiterated RatingNeutral$95.00 ➝ $112.00N/A
i
10/9/2017Jefferies Financial GroupBoost Price TargetBuy$120.00 ➝ $130.00N/A
i
9/19/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$110.00Medium
i
9/12/2017Jefferies Financial GroupReiterated RatingBuy$120.00Low
i
9/1/2017Robert W. BairdReiterated RatingBuy$114.00Low
i
7/19/2017BarclaysReiterated RatingHold$102.00Low
i
Rating by Jack Meehan at Barclays PLC
6/30/2017Jefferies Financial GroupReiterated RatingBuy$121.00Low
i
6/28/2017CitigroupReiterated RatingNeutral$91.00 ➝ $104.00Low
i
6/14/2017Jefferies Financial GroupReiterated RatingBuyLow
i
6/6/2017Credit Suisse GroupReiterated RatingNeutral$89.00 ➝ $95.00Low
i
5/13/2017BarclaysSet Price TargetHold$90.00Low
i
Rating by Jack Meehan at Barclays PLC
5/11/2017CitigroupReiterated RatingNeutral$90.00 ➝ $104.00Low
i
4/21/2017Jefferies Financial GroupReiterated RatingBuy$106.00Low
i
3/16/2017Jefferies Financial GroupReiterated RatingBuyHigh
i
2/15/2017UBS GroupBoost Price Target$84.00N/A
i
2/15/2017Jefferies Financial GroupBoost Price TargetBuy$104.00N/A
i
1/4/2017Evercore ISIUpgradeHold ➝ Buy$86.50N/A
i
12/20/2016Jefferies Financial GroupReiterated RatingBuy$93.00N/A
i
12/16/2016The Goldman Sachs GroupUpgradeSell ➝ Neutral$75.00 ➝ $77.00N/A
i
11/30/2016BarclaysUpgradeUnderweight ➝ Equal Weight$65.00 ➝ $77.00N/A
i
11/18/2016Bank of AmericaSet Price TargetBuy$93.00N/A
i
9/30/2016Credit Suisse GroupReiterated RatingHold ➝ NeutralN/A
i
Rating by Erin Wilson at Credit Suisse Group AG
9/6/2016UBS GroupDowngradeNeutral ➝ Sell$83.00 ➝ $78.00N/A
i
8/4/2016Evercore ISIReiterated RatingHold$83.50 ➝ $91.50N/A
i
8/4/2016Jefferies Financial GroupBoost Price TargetBuy$94.00 ➝ $100.00N/A
i
8/4/2016CitigroupBoost Price TargetNeutral$85.00 ➝ $90.00N/A
i
6/20/2016Credit Suisse GroupInitiated CoverageNeutral$84.00N/A
i
5/22/2016KeyCorpReiterated RatingHold$77.00N/A
i
5/20/2016BarclaysBoost Price TargetUnderweight$60.00 ➝ $65.00N/A
i
5/5/2016UBS GroupReiterated RatingNeutral$76.00 ➝ $83.00N/A
i
4/26/2016GabelliInitiated CoverageBuy$96.00N/A
i
Rating by S. Wojda at Gabelli
2/11/2016Jefferies Financial GroupReiterated RatingBuy$96.00 ➝ $90.00N/A
i
2/11/2016Bank of AmericaReiterated RatingBuy$90.00 ➝ $87.00N/A
i
2/11/2016UBS GroupBoost Price TargetNeutral$75.00 ➝ $76.00N/A
i
2/11/2016Jefferies Financial GroupLower Price TargetBuy$96.00 ➝ $90.00N/A
i
Rating by David Windley at Jefferies Financial Group Inc.
2/11/2016The Goldman Sachs GroupBoost Price TargetSell$71.00 ➝ $74.00N/A
i
2/11/2016Deutsche Bank AktiengesellschaftReiterated RatingHold$85.00 ➝ $82.00N/A
i
Rating by George Hill at Deutsche Bank Aktiengesellschaft
(Data available from 1/22/2016 forward)
Charles River Laboratories International logo
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company has a strategic partnership with PathoQuest SAS to establish a next generation sequencing based testing laboratory. Charles River Laboratories International, Inc. is based in Wilmington, Massachusetts.
Read More

Today's Range

Now: $280.18
$277.36
$282.09

50 Day Range

MA: $254.58
$236.27
$282.94

52 Week Range

Now: $280.18
$95.58
$284.60

Volume

169,367 shs

Average Volume

325,216 shs

Market Capitalization

$13.94 billion

P/E Ratio

46.70

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Charles River Laboratories International?

The following sell-side analysts have issued research reports on Charles River Laboratories International in the last year: Argus, Bank of America Co., Barclays PLC, Cfra, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., JPMorgan Chase & Co., KeyCorp, Morgan Stanley, Robert W. Baird, Smith Barney Citigroup, SunTrust Banks, Inc., Truist, UBS Group AG, Wells Fargo & Company, Wolfe Research, and Zacks Investment Research.

What is the current price target for Charles River Laboratories International?

18 Wall Street analysts have set twelve-month price targets for Charles River Laboratories International in the last year. Their average twelve-month price target is $214.67, suggesting a possible downside of 23.4%. Argus has the highest price target set, predicting CRL will reach $265.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $145.00 for Charles River Laboratories International in the next year.

What is the current consensus analyst rating for Charles River Laboratories International?

Charles River Laboratories International currently has 4 hold ratings, 13 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRL will outperform the market and that investors should add to their positions of Charles River Laboratories International.

What other companies compete with Charles River Laboratories International?

How do I contact Charles River Laboratories International's investor relations team?

Charles River Laboratories International's physical mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company's listed phone number is 781-222-6000 and its investor relations email address is [email protected] The official website for Charles River Laboratories International is www.criver.com.